一种用于儿童癫痫大发作的药物：三年缓解期的医学审计

One drug for childhood grand mal: medical audit for three-year remissions.

作者信息

Forsythe W I, Sills M A

出版信息

Dev Med Child Neurol. 1984 Dec;26(6):742-8. doi: 10.1111/j.1469-8749.1984.tb08167.x.

DOI:10.1111/j.1469-8749.1984.tb08167.x

Abstract

A comparative study was made of monotherapy for grand mal seizures among four groups of children between three and 14 years of age. The first-choice anticonvulsants were phenobarbitone (N = 159), phenytoin (N = 185), carbamazepine (N = 178) and sodium valproate (N = 63). The proportions in each group with a three-year remission of seizures were, respectively, 22, 34, 40 and 16 per cent. The results were better for children with primary grand mal (25, 39, 45 and 21 per cent) and were worse for those with secondary grand mal (3, 21, 25 and 4 per cent), respectively. 119 of the children obtained no reduction in seizure frequency, and for them there is an urgent need for new and more effective anticonvulsants.

摘要

对3至14岁的四组儿童进行了大发作癫痫单一疗法的比较研究。首选抗惊厥药物为苯巴比妥（N = 159）、苯妥英（N = 185）、卡马西平（N = 178）和丙戊酸钠（N = 63）。每组中癫痫发作缓解三年的比例分别为22%、34%、40%和16%。原发性大发作儿童的结果更好（分别为25%、39%、45%和21%），继发性大发作儿童的结果更差（分别为3%、21%、25%和4%）。119名儿童的癫痫发作频率没有降低，因此迫切需要新的、更有效的抗惊厥药物。